Alcohol dependence is classified as a disease - but there is no effective treatment. The need for new medicines is great. We have the necessary expertise to bridge the gap between basic research and the clinic and thus accelerate drug development. One challenge in the treatment of alcohol dependence is to prevent relapse, which is driven by a strong craving for alcohol that persists even after long-term sobriety. In addition, the ability to resist cravings is limited as alcohol dependent people have impaired impulse control. Dopamine increases when you drink alcohol - you feel drunk. However, with repeated intoxication, dopamine levels decrease, creating discomfort - a strong alcohol craving - which can drive alcohol dependent individuals to start drinking again. Dopamine is also involved in impaired impulse control. The dopamine system is therefore a potential target for new drugs to treat alcohol dependence. Dopamine stabilizers are a new group of drugs (developed by Nobel laureate Arvid Carlsson) that can normalize dopamine levels in the brain. Something that is sought in the effective treatment of alcohol dependence. Our results show that the dopamine stabilizer OSU6162 reduces alcohol intake and relapse drinking in rats. We will now study how OSU6162 affects the release of dopamine in the brain and whether OSU6162 itself is addictive. We will also study for the first time whether OSU6162 can reduce alcohol craving and improve impulse control in alcohol-dependent people.